Treatment of Leprosy with Clofazimine, Rifampicin and Bayrena
J. LANGUILLON
Abstract
Open-access reader
J. LANGUILLON
Abstract
Open-access reader
In Africa, 8% of leprosy patients have the lepromatous form, and 85% have the tuberculoid form of the disease.Treating these patients with dapsone needs severa] years to produce good results, treatment with acedapsone is still in the experimental st age, and rifampicin is too expensive.There are two drugs remaining; clofazimine, which is the treatment of choice for those with lepromatous leprosy, and sulphanilamides, treatment for the tuberculoid form of leprosy and for acute inflammation af the peripheral nerves.
OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In Africa, 8% of leprosy patients have the lepromatous form, and 85% have the tuberculoid form of the disease.Treating these patients with dapsone needs severa] years to produce good results, treatment with acedapsone is still in the experimental st age, and rifampicin is too expensive.There are two drugs remaining; clofazimine, which is the treatment of choice for those with lepromatous leprosy, and sulphanilamides, treatment for the tuberculoid form of leprosy and for acute inflammation af the peripheral nerves.
Key concepts: Clofazimine, Rifampicin, Leprosy, Medicine, Tuberculosis, Dapsone, Dermatology, Pathology